Citadel Advisors
NMTR

Citadel Advisors’s 9 Meters Biopharma NMTR Stock Holding History

Citadel Advisors’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-200
Closed -$134 – 15598
2023
Q2 		$134 Sell
200
-11,700
-98% -$10.3K ﹤0.01% 14211
2023
Q1 		$16.5K Buy
11,900
+8,735
+276% +$16.5K ﹤0.01% 13195
2022
Q4 		$3.99K Buy
+3,165
New +$7.22K ﹤0.01% 14148
2022
Q2 		– Sell
-1,000
Closed -$12K – 14567
2022
Q1 		$12K Sell
1,000
-3,355
-77% -$45.8K ﹤0.01% 13365
2021
Q4 		$85K Sell
4,355
-5,550
-56% -$124K ﹤0.01% 12884
2021
Q3 		$258K Buy
9,905
+4,940
+99% +$116K ﹤0.01% 11415
2021
Q2 		$109K Buy
4,965
+3,110
+168% +$76.3K ﹤0.01% 12847
2021
Q1 		$43K Sell
1,855
-40
-2% -$1.23K ﹤0.01% 12961
2020
Q4 		$33K Buy
+1,895
New +$31.6K ﹤0.01% 10694
2019
Q1 		– Sell
-670
Closed -$31K – 10065
2018
Q4 		$31K Sell
670
-475
-41% -$35.2K ﹤0.01% 8613
2018
Q3 		$156K Buy
+1,145
New +$197K ﹤0.01% 8374

Other funds holding NMTR

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SIS
Strategic Investment Solutions Orland Park, Illinois $437M AUM 30.41% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $537M AUM 12.29% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
RFA
Register Financial Advisors Atlanta, Georgia $326M AUM 48.38% 1-Year Est. Return

Citadel Advisors's NMTR Position: Q3 2023 in Review

Citadel Advisors sold out of 9 Meters Biopharma (NMTR) in Q3 2023, closing a stake of 1,388 shares — an estimated $933 sold.

Citadel Advisors first reported a position in NMTR in Q4 2016 and held it in 16 quarters. The position peaked at $259K in Q1 2021. 6 funds tracked by Wall St. Rank hold NMTR as of Q3 2023.

  • Citadel Advisors reported no remaining 9 Meters Biopharma position as of Q3 2023 after selling out during the quarter.
  • Citadel Advisors sold 1,388 9 Meters Biopharma shares in Q3 2023, an estimated $933.
  • Citadel Advisors first reported a position in 9 Meters Biopharma in Q4 2016 and held it in 16 quarters.
  • Citadel Advisors's 9 Meters Biopharma position peaked at $259K in Q1 2021.
  • 6 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.